Search Results - "FRONTINI, L"

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients by Ruzzo, A, Graziano, F, Galli, Fabio, Galli, Francesca, Rulli, E, Lonardi, S, Ronzoni, M, Massidda, B, Zagonel, V, Pella, N, Mucciarini, C, Labianca, R, Ionta, M T, Bagaloni, I, Veltri, E, Sozzi, P, Barni, S, Ricci, V, Foltran, L, Nicolini, M, Biondi, E, Bramati, A, Turci, D, Lazzarelli, S, Verusio, C, Bergamo, F, Sobrero, A, Frontini, L, Menghi, M, Magnani, M

“…Background: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause…”
Get full text

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer by Scagliotti, G V, De Marinis, F, Rinaldi, M, Crinò, L, Gridelli, C, Ricci, S, Matano, E, Boni, C, Marangolo, M, Failla, G, Altavilla, G, Adamo, V, Ceribelli, A, Clerici, M, Di Costanzo, F, Frontini, L, Tonato, M

“…To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for…”
Get full text

Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial by Gridelli, Cesare, Perrone, Francesco, Gallo, Ciro, Cigolari, Silvio, Rossi, Antonio, Piantedosi, Francovito, Barbera, Santi, Ferraù, Francesco, Piazza, Elena, Rosetti, Francesco, Clerici, Maurizia, Bertetto, Oscar, Robbiati, Sergio Federico, Frontini, Luciano, Sacco, Cosimo, Castiglione, Federico, Favaretto, Adolfo, Novello, Silvia, Migliorino, Maria Rita, Gasparini, Giampietro, Galetta, Domenico, Iaffaioli, Rosario Vincenzo, Gebbia, Vittorio

“…Background: Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC). Some studies have…”
Get full text

Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients by Gelsomino, F., Torri, V., Zaniboni, A., Labianca, R., Sobrero, A., Poli, D., Frontini, L., Cascinu, S.

Get full text

Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients by Arenare, L, Porta, C, Barberio, D, Terzolo, S, Zagonel, V, Pisconti, S, Del Mastro, L, Pinto, C, Bilancia, D, Cinieri, S, Rizzo, M, Migliaccio, G, Montesarchio, V, Del Campo, L, De Lorenzo, F, Iannelli, E, Traclò, F, Gitto, L, Vaccaro, M C, Frontini, L, Giannarelli, D, Bryce, J, Piccirillo, M C, Jommi, C, Efficace, F, Riva, S, Di Maio, M, Gallo, C, Perrone, F

“…The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire was developed to measure financial toxicity (FT) and identify its…”
Get full text

FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial by Zaniboni, A., Lonardi, S., Labianca, R., Di Bartolomeo, M., Rosati, G., Ronzoni, M., Pella, N., Banzi, M., Zampino, M.G., Pasini, F., Marchetti, P., Rimassa, L., Maiello, E., Bidoli, P., Cinieri, S., Barni, S., Ciuffreda, L., Beretta, G., Frontini, L., Rulli, E., Sobrero, A.

Get full text

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer by DI MAIO, M, GRIDELLI, C, FRONTINI, L, ROSETTI, F, CARROZZA, F, BEARZ, A, SPATAFORA, M, ADAMO, V, ISA, L, LAFFAIOLI, R. V, DI SALVO, E, PERRONE, F, GALLO, C, MANZIONE, L, BRANCACCIO, L, BARBERA, S, ROBBIATI, S. F, LANNIELLO, G. P, FERRAU, F, PIAZZA, E

“…Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was…”
Get full text

Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors by LISSONI, P, BRIVIO, F, FUMAGALLI, L, MESSINA, G, GHEZZI, V, FRONTINI, L, GIANI, L, VAGHI, M, ARDIZZOIA, A, GARDANI, G. S

“…The evidence of lymphocytopenia has been demonstrated to predict a poor prognosis in terms of survival in advanced cancer patients. This finding is not…”
Get full text

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) by CASCINU, S, SILVA, R. R, FUSCO, V, LUPORINI, G, CELLERINO, R, CATALANO, G, BARNI, S, LABIANCA, R, FRONTINI, L, PIAZZA, E, PANCERA, G, GIORDANI, P, GIULIODORI, L, PESSI, M. A

“…In a randomized clinical trial, gemcitabine (GEM) was more effective than 5-fluorouracil (5-FU) in advanced pancreatic cancer patients. GEM and 5-FU have…”
Get full text

A Phase II Study of Tamoxifen in Hormone-resistant Metastatic Prostate Cancer: Possible Relation with Prolactin Secretion by LISSONI, P, VIGANO, P, VAGHI, M, FRONTINI, L, GIUBERTI, C, MANGANINI, V, CASU, M, BRIVIO, F, NIESPOLO, R, STRADA, G

“…Recent experimental observations, showing the potential role of prolactin (PRL) as a tumor growth factor for prostate cancer and the unfavourable prognostic…”
Get full text

Radiation Tolerant Multi-Gigabit Serializer for data readout in High Energy Physics experiments by Magazzu, G., Minuti, M., Palla, F., Frontini, L., Stabile, A., Ciarpi, G.

“…This paper describes the SER28_V1 circuit: including thea prototype of an 8 Gbps 20-bit Serializer developed in a commercial CMOS 28nm technology. The circuit…”
Get full text

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer by CASCINU, S, GRAZIANO, F, BARNI, S, LABIANCA, R, COMELLA, G, CASARETTI, R, FRONTINI, L, CATALANO, V, BALDELLI, A. M, CATALANO, G

“…In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of…”
Get full text

Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) by Cascinu, S., Labianca, R., Catalano, V., Barni, S., Ferraù, F., Beretta, G. D., Frontini, L., Foa, P., Pancera, G., Priolo, D., Graziano, F., Mare, M., Catalano, G.

“…Background: This phase II study was initiated to determine the activity and toxicity of a combination of gemcitabine (GEM) and cisplatin (CDDP) in patients…”
Get full text

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses by GRIDELLI, C, FRONTINI, L, FARRIS, A, LOCATELLI, M. C, FELLETTI, R, PIAZZA, E, PERRONE, F, GALLO, C, GULISANO, M, CIGOLARI, S, CASTIGLIONE, F, ROBBIATI, S. F, GASPARINI, G, LANNIELLO, G. P

“…Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated…”
Get full text

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study by Gasparini, G, Caffo, O, Barni, S, Frontini, L, Testolin, A, Guglielmi, R B, Ambrosini, G

“…To evaluate the efficacy and toxicity of single-agent vinorelbine (VNB), a semisynthetic vinca alkaloid, in patients with breast cancer previously treated with…”
Get more information

Layered material characterization using ultrasonic transmission. An inverse estimation methodology by Messineo, María G, Rus, Guillermo, Eliçabe, Guillermo E, Frontini, Gloria L

“…This paper presents an inverse methodology with the aim to characterize a layered material through the identification of acoustical and mechanical properties…”
Get full text

Enhancement of the Efficacy of Weekly Low-dose Taxotere by the Long Acting Anti-prolactinemic Drug Cabergoline in Pretreated Metastatic Breast Cancer by FRONTINI, L, LISSONI, P, VAGHI, M, PEREGO, M. S, PESCIA, S, ARDIZZOIA, A, GARDANI, G

“…In view of its potential action as a growth factor, the evidence of abnormally high blood levels of prolactin (PRL) is associated with a poor prognosis in…”
Get full text

Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer by Cascinu, S, Labianca, R, Alessandroni, P, Marcellini, M, Silva, R R, Pancera, G, Testa, E, Martignoni, G, Barni, S, Frontini, L, Zaniboni, A, Luporini, G, Cellerino, R, Catalano, G

“…A multiinstitutional trial was performed to confirm the clinical activity, in terms of response rate and toxicity (primary objectives) and duration of…”
Get more information

Design of Non-Metastable SRAM Cells in 28 nm CMOS Technology by Crescioli, F., Frontini, L., Liberali, V., Stabile, A.

“…This paper presents the design of an SRAM cell in 28 nm, specifically designed to avoid metastability at start-up. Metastable operation is avoided by…”
Get full text

A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) by Cascinu, S., Frontini, L., Labianca, R., Catalano, V., Barni, S., Graiff, C., Picone, G., Farinati, F., Zonato, S., Pessi, M. A., Curti, C., Catalano, G.

“…Background: Laboratory evidences suggest the possibility that an infusion rate of 10 mg/m2/min may be more effective than the standard 30-min infusion of…”
Get full text